Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...
Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat ...
Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...
Pop Mart, the Chinese firm behind the mischievously grinning, nine-toothed Labubu dolls that shoppers have queued up to buy ...
Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...
Novo Nordisk trades 32% below fair value with a 3.6% yield, semaglutide at 74% of sales, EPS rebound post '26, and pipeline ...
NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S.
Meanwhile, the 25-milligram dose of Novo Nordisk's oral semaglutide helped patients lose up to 16.6% of their weight on ...
NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger ...
The imminent Indian patent expiry of Novo Nordisk’s global blockbuster anti-diabetic and weight loss treatment drug – the GLP ...
Novo Nordisk said on Thursday it had filed a marketing application with the U.S. Food and Drug Administration for CagriSema, ...
Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push a new generation of obesity treatments while making sweeping changes to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results